JPWO2020102142A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020102142A5 JPWO2020102142A5 JP2021525119A JP2021525119A JPWO2020102142A5 JP WO2020102142 A5 JPWO2020102142 A5 JP WO2020102142A5 JP 2021525119 A JP2021525119 A JP 2021525119A JP 2021525119 A JP2021525119 A JP 2021525119A JP WO2020102142 A5 JPWO2020102142 A5 JP WO2020102142A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleosides
- composition
- subscript
- modified oligonucleotide
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862760546P | 2018-11-13 | 2018-11-13 | |
| US62/760,546 | 2018-11-13 | ||
| PCT/US2019/060841 WO2020102142A1 (en) | 2018-11-13 | 2019-11-12 | Microrna compounds and methods for modulating mir-10b activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022506958A JP2022506958A (ja) | 2022-01-17 |
| JPWO2020102142A5 true JPWO2020102142A5 (https=) | 2022-10-03 |
| JP2022506958A5 JP2022506958A5 (https=) | 2022-10-03 |
Family
ID=68808539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021525119A Pending JP2022506958A (ja) | 2018-11-13 | 2019-11-12 | Ｍｉｒ－１０ｂ活性を調節するためのマイクロｒｎａ化合物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220096517A1 (https=) |
| EP (1) | EP3880310A1 (https=) |
| JP (1) | JP2022506958A (https=) |
| KR (1) | KR20210091732A (https=) |
| CN (1) | CN112996568A (https=) |
| AU (1) | AU2019381681A1 (https=) |
| CA (1) | CA3117981A1 (https=) |
| MA (1) | MA54226A (https=) |
| TW (1) | TW202031268A (https=) |
| WO (1) | WO2020102142A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11236337B2 (en) | 2016-11-01 | 2022-02-01 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
| US11584932B2 (en) | 2016-11-01 | 2023-02-21 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
| WO2021262919A2 (en) | 2020-06-26 | 2021-12-30 | The Research Foundation For The State University Of New York | 5-halouracil-modified micrornas and their use in the treatment of cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3192788A1 (en) | 2006-10-03 | 2017-07-19 | Arbutus Biopharma Corporation | Lipid containing formulations |
| CN102186998A (zh) * | 2008-08-19 | 2011-09-14 | 人类遗传学与健康缅因州研究院 | 微小rna和1型神经纤维瘤病在诊断和治疗中 |
| ES2555057T3 (es) * | 2009-06-12 | 2015-12-28 | Roche Innovation Center Copenhagen A/S | Nuevos potentes compuestos antisentido anti-ApoB |
| EP2490699A1 (en) * | 2009-10-20 | 2012-08-29 | Santaris Pharma A/S | Oral delivery of therapeutically effective lna oligonucleotides |
| EP2753692B1 (en) * | 2011-09-07 | 2019-03-27 | 3-D Matrix Ltd. | Microrna-based methods and assays for osteosarcoma |
| PE20142404A1 (es) * | 2012-04-25 | 2015-02-02 | Regulus Therapeutics Inc | Compuestos de microarn y metodos de modulacion de la actividad de mir-21 |
| IL322679A (en) * | 2016-12-05 | 2025-10-01 | Regulus Therapeutics Inc | Modified oligonucleotides for the treatment of polycystic kidney disease |
-
2019
- 2019-11-12 KR KR1020217016717A patent/KR20210091732A/ko not_active Withdrawn
- 2019-11-12 CN CN201980074354.1A patent/CN112996568A/zh active Pending
- 2019-11-12 TW TW108140918A patent/TW202031268A/zh unknown
- 2019-11-12 WO PCT/US2019/060841 patent/WO2020102142A1/en not_active Ceased
- 2019-11-12 JP JP2021525119A patent/JP2022506958A/ja active Pending
- 2019-11-12 MA MA054226A patent/MA54226A/fr unknown
- 2019-11-12 EP EP19817004.5A patent/EP3880310A1/en not_active Withdrawn
- 2019-11-12 US US17/290,298 patent/US20220096517A1/en not_active Abandoned
- 2019-11-12 AU AU2019381681A patent/AU2019381681A1/en not_active Abandoned
- 2019-11-12 CA CA3117981A patent/CA3117981A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hotte et al. | An optimized clinical regimen for the oncolytic virus PV701 | |
| JP4307775B2 (ja) | Ｃｓｆ−１インヒビターの使用 | |
| Messaoudi et al. | Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide | |
| JP2022159552A (ja) | ｉＮＯＳ阻害組成物および乳がん治療薬としてのその使用 | |
| US11403008B2 (en) | Methods of using OX40 ligand encoding polynucleotides | |
| CN116726203A (zh) | 编码免疫调节多肽的mrna的组合及其用途 | |
| JP2022506958A5 (https=) | ||
| KR101843985B1 (ko) | 암을 치료하기 위한 조성물과 방법 | |
| CN117343965A (zh) | 核酸载体、核酸药及其制备方法和应用 | |
| WO2009114459A2 (en) | Anti-neoplastic combination therapeutic regimen involving co-disruption of parp pathway and mre11/rad50/nbs1 complex and compositons useful therein | |
| US20190269711A1 (en) | Methods of treating cancer | |
| RU2535993C2 (ru) | Молекула rnai, нацеливающая тимидилатсинтазу и ее применение | |
| JPWO2020102142A5 (https=) | ||
| CN101522898A (zh) | 使用Bcl-XL特异性siNA的癌症疗法 | |
| KR101843984B1 (ko) | 췌장암을 치료하기 위한 조성물과 방법 | |
| US20080274121A1 (en) | Inhibition of Angiogenesis by Mithramycin | |
| CN114574495A (zh) | 核苷类衍生物改性的核酸适体r50 | |
| JP6574136B2 (ja) | Ｅｇｆｒの発現をサイレンシングするためのｄｎａザイム | |
| WO2022182795A1 (en) | Nucleic acid vectors and methods of use | |
| JP2023519580A (ja) | 治療抵抗性ｍｕｃ４＋癌を処置するための方法 | |
| JP7707184B2 (ja) | 修飾短干渉ｒｎａ組成物、及びがんの処置におけるそれらの使用 | |
| US20250304975A1 (en) | Aptamer and ribozyme equilibrium shifting (ares) rna circuits and uses thereof | |
| US20110268763A1 (en) | Polynucleotides that stimulate neutrophils | |
| KR20230131934A (ko) | 암을 치료하기 위한 조합 치료요법 스케줄 | |
| WO2013082449A2 (en) | Treatment of b cell lymphomas |